Suppr超能文献

来自奥昔康家族的非甾体抗炎药对细胞因子诱导的白细胞黏附受体变化的预防作用。

Prevention of cytokine-induced changes in leukocyte adhesion receptors by nonsteroidal antiinflammatory drugs from the oxicam family.

作者信息

García-Vicuña R, Díaz-González F, González-Alvaro I, del Pozo M A, Mollinedo F, Cabañas C, González-Amaro R, Sánchez-Madrid F

机构信息

Servicio de Inmunología, Hospital de la Princesa, Madrid, Spain.

出版信息

Arthritis Rheum. 1997 Jan;40(1):143-53. doi: 10.1002/art.1780400119.

Abstract

OBJECTIVE

To explore the effect of the nonsteroidal antiinflammatory drugs (NSAIDs) piroxicam and meloxicam on quantitative and qualitative changes in leukocyte adhesion receptors induced by cytokines and other activation stimuli.

METHODS

The expression of CD11b and L-selectin during neutrophil activation with tumor necrosis factor alpha (TNF alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF), FMLP, phorbol myristate acetate (PMA), and calcium ionophore A23187 was assessed by flow cytometry. Enzyme-linked immunosorbent assays were used to quantitate soluble L-selectin shed after neutrophil stimulation. Enzyme release was measured to determine neutrophil degranulation by proinflammatory stimuli. Changes in affinity state of beta 1 and beta 2 integrins after neutrophil and T lymphocyte stimulation were assessed, by flow cytometry, using the monoclonal antibodies (MAb) HUTS-21 (anti-beta 1) and CBRM1/5 (anti-CD11b), which recognize activation-dependent epitopes on these two integrins.

RESULTS

Pretreatment of neutrophils with either NSAID prevented the changes in L-selectin and CD11b expression induced by TNF alpha, GM-CSF, and FMLP, but not those induced by PMA or A23187. Furthermore, piroxicam significantly decreased the amount of L-selectin shed by cytokine-treated neutrophils, whereas it did not exert this effect on PMA- or A23187-treated neutrophils. Piroxicam also decreased the release of gelatinase and lysozyme induced by TNF alpha, but not by PMA. Interestingly, piroxicam prevented the conformational changes that beta 2 integrins underwent upon activation of neutrophils: the appearance of the activation epitope of CD11b, detected by the CBRM1/5 MAb, was blocked by piroxicam in TNF alpha-treated neutrophils. Moreover, in chemokine-treated T lymphocytes, the expression of activation epitopes on beta 1 integrins was also diminished by piroxicam. In contrast, this NSAID did not affect the beta 1 integrin conformational changes induced by PMA or Mn++.

CONCLUSION

Our results indicate that members of the oxicam family are able to interfere with events of neutrophil function, such as their degranulation and cytokine-mediated activation changes in adhesion molecules, both in neutrophils and in lymphocytes. Such effects may significantly contribute to the antiinflammatory activity of these drugs.

摘要

目的

探讨非甾体抗炎药(NSAIDs)吡罗昔康和美洛昔康对细胞因子及其他激活刺激诱导的白细胞黏附受体定量和定性变化的影响。

方法

通过流式细胞术评估肿瘤坏死因子α(TNFα)、粒细胞-巨噬细胞集落刺激因子(GM-CSF)、N-甲酰甲硫氨酸-亮氨酸-苯丙氨酸(FMLP)、佛波酯(PMA)和钙离子载体A23187激活中性粒细胞过程中CD11b和L-选择素的表达。采用酶联免疫吸附测定法对中性粒细胞刺激后释放的可溶性L-选择素进行定量。通过测量酶释放来确定促炎刺激引起的中性粒细胞脱颗粒情况。使用识别这两种整合素上激活依赖性表位的单克隆抗体(MAb)HUTS-21(抗β1)和CBRM1/5(抗CD11b),通过流式细胞术评估中性粒细胞和T淋巴细胞刺激后β1和β2整合素亲和力状态的变化。

结果

用任何一种NSAID预处理中性粒细胞均可防止TNFα、GM-CSF和FMLP诱导的L-选择素和CD11b表达变化,但不能防止PMA或A23187诱导的变化。此外,吡罗昔康显著降低细胞因子处理的中性粒细胞释放的L-选择素量,而对PMA或A23187处理的中性粒细胞则无此作用。吡罗昔康还可降低TNFα诱导的明胶酶和溶菌酶释放,但对PMA诱导的释放无此作用。有趣的是,吡罗昔康可防止中性粒细胞激活时β2整合素发生的构象变化:在TNFα处理的中性粒细胞中,CBRM1/5 MAb检测到的CD11b激活表位的出现被吡罗昔康阻断。此外,在趋化因子处理的T淋巴细胞中,吡罗昔康也可降低β1整合素上激活表位的表达。相比之下,这种NSAID不影响PMA或Mn++诱导的β1整合素构象变化。

结论

我们的结果表明,昔康类药物能够干扰中性粒细胞功能事件,如它们的脱颗粒以及中性粒细胞和淋巴细胞中细胞因子介导的黏附分子激活变化。这些作用可能对这些药物的抗炎活性有显著贡献。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验